Skip to main content
Premium Trial:

Request an Annual Quote

Sue Siegel, Christian Cabou, Ulf Boberg, Carl-Johan Dalsgaard, Stephen Scherer, Andrew Crescenzo, Hkon Hkonarson, Tomas Sigurdsson, DNA Chip Research, GeneGo

Premium

People in the News

Sue Siegel will receive an annual base salary of $426,315, plus benefits, for her role as president emeritus of Affymetrix, according to an 8-K filed with the US Securities and Exchange Commission this week

In the event that Siegel's employment is terminated or she resigns before November 19, 2007, she will be entitled to receive a payment equal to $675,000 less the base salary paid from April 19, 2006 through the date of termination of employment; continued company-paid health coverage through October 19, 2007, according to the document. Siegel will also be entitled to an accelerated vesting of existing stock options to the extent they would have vested if Siegel had remained employed through October 19, 2007.

Siegel became president emeritus after resigning from her position as president of Affymetrix in April (see BAN 4/25/2006).


Illumina last week appointed Christian Cabou as senior vice president and general counsel.

Cabou most recently served as general counsel of GE Global Research. Earlier, he was senior counsel of global intellectual property of GE Medical Systems. He also spent nearly seven years with the firm of Foley & Lardner, where he was a partner.

Cabou received his JD from Northwestern University School of Law in Chicago. He holds a master of engineering management from Northwestern University as well as an MSEE degree from the Conservatoire National des Arts et Metiers in Paris and a BS from the Lycee Technique d'Etat in Armentieres, France.


Affibody named Ulf Boberg as its new chief executive officer last week.

He replaces Carl-Johan Dalsgaard, who has been acting CEO since December 2005. Dalsgaard is a partner of Affibody's largest shareholder, HealthCap, and will remain a non-executive Affibody director, the company said.

Boberg came to Affibody in January 2006 as senior vice president for development. Prior to that, he was CEO of Global Genomics. He also held the senior roles of vice president and head of the development division at Astra Pain Control, vice president and R&D site general manager at AstraZeneca, head of medical research at Gambro, CEO of PMC Clinical Research, and CEO of Alfta Rehab Center.


Stephen Scherer has joined CombiMatrix Molecular Diagnostics' science advisory board, CMDX said last week. CombiMatrix Molecular Diagnostics is wholly owned by CombiMatrix.

Scherer is a senior scientist in genetics and genomic biology at the Hospital for Sick Children in Canada and associate professor of medicine at the University of Toronto. He is also director of the Center for Applied Genomics and associate chief of research at the hospital.


Andrew Crescenzo has been named as senior vice president of finance at Enzo Biochem, the company said this week.

A certified public accountant, Crescenzo previously served as an executive director of Grant Thornton LLP. Prior to Grant Thornton, Crescenzo was vice president and chief financial officer of J. D'Addario & Co. Before that he was a senior manager with the accounting firm of Ernst and Young LLP.


Håkon Håkonarson is leaving DeCode Genetics to pursue other interests, the company said last week.

Håkonarson has been with DeCode for eight years and held various positions, most recently as vice president of business development.


Tomas Sigurdsson, DeCode's vice president of treasury and new alliances, will assume responsibility for the company's business development

New Product Watch

DNA Chip Research said this week that it has launched the 3D-Gene Yeast Oligo Chip 6K, a whole-genome yeast array for research purposes.

The chip was developed with Toray Industries and uses DNA Chip Research's ProbeBank oligo probe design, and can analyze genes that have lower expression levels, DCR claimed.

DNA Chip Research said it will introduce a human genome chip in the next six months.


GeneGo this week said that its MetaCore data mining platform is now interoperable with Agilent Technologies' GeneSpring microarray analysis and data management applications.

Users will now be able to integrate both into their statistical and functional analysis of gene expression data.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.